Research ExplorerPublicationsUpdate Breast Cancer 2021 Part 4 - Prevention and Early Stag...

Update Breast Cancer 2021 Part 4 - Prevention and Early Stages

Standard

Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. / Thomssen, Christoph; Fehm, Tanja N; Stickeler, Elmar; Fasching, Peter A; Janni, Wolfgang; Kolberg-Liedtke, Cornelia; Kolberg, Hans-Christian; Lüftner, Diana; Müller, Volkmar; Schütz, Florian; Belleville, Erik; Bader, Simon; Untch, Michael; Welslau, Manfred; Thill, Marc; Hartkopf, Andreas D; Tesch, Hans; Ditsch, Nina; Lux, Michael P; Wöckel, Achim; Aktas, Bahriye; Schneeweiss, Andreas; Würstlein, Rachel.

In: GEBURTSH FRAUENHEILK, Vol. 82, No. 2, 02.2022, p. 206-214.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Thomssen, C, Fehm, TN, Stickeler, E, Fasching, PA, Janni, W, Kolberg-Liedtke, C, Kolberg, H-C, Lüftner, D, Müller, V, Schütz, F, Belleville, E, Bader, S, Untch, M, Welslau, M, Thill, M, Hartkopf, AD, Tesch, H, Ditsch, N, Lux, MP, Wöckel, A, Aktas, B, Schneeweiss, A & Würstlein, R 2022, 'Update Breast Cancer 2021 Part 4 - Prevention and Early Stages', GEBURTSH FRAUENHEILK, vol. 82, no. 2, pp. 206-214. https://doi.org/10.1055/a-1724-9639

APA

Thomssen, C., Fehm, T. N., Stickeler, E., Fasching, P. A., Janni, W., Kolberg-Liedtke, C., Kolberg, H-C., Lüftner, D., Müller, V., Schütz, F., Belleville, E., Bader, S., Untch, M., Welslau, M., Thill, M., Hartkopf, A. D., Tesch, H., Ditsch, N., Lux, M. P., ... Würstlein, R. (2022). Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. GEBURTSH FRAUENHEILK, 82(2), 206-214. https://doi.org/10.1055/a-1724-9639

Vancouver

Thomssen C, Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C et al. Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. GEBURTSH FRAUENHEILK. 2022 Feb;82(2):206-214. https://doi.org/10.1055/a-1724-9639

Bibtex

@article{a38b1c65560641189b2a1ade5e44531e,
title = "Update Breast Cancer 2021 Part 4 - Prevention and Early Stages",
abstract = "This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In triple-negative disease, data were presented for two treatment regimens. Patients with advanced disease (stage 2 and 3) benefit from neoadjuvant treatment with the immune checkpoint inhibitor pembrolizumab in combination with standard chemotherapy, regardless of PD-L1 expression. When neoadjuvant therapy has failed to achieve the desired remission in BRCA1 and BRCA2 mutations, the administration of the PARP inhibitor olaparib has demonstrated an impressive response. Other data address translational issues in HER2-positive breast cancer and neoadjuvant therapy approaches with the oral SERD giredestrant and the PARP inhibitor talazoparib. This review presents and analyses the findings of this year' s most important study outcomes.",
author = "Christoph Thomssen and Fehm, {Tanja N} and Elmar Stickeler and Fasching, {Peter A} and Wolfgang Janni and Cornelia Kolberg-Liedtke and Hans-Christian Kolberg and Diana L{\"u}ftner and Volkmar M{\"u}ller and Florian Sch{\"u}tz and Erik Belleville and Simon Bader and Michael Untch and Manfred Welslau and Marc Thill and Hartkopf, {Andreas D} and Hans Tesch and Nina Ditsch and Lux, {Michael P} and Achim W{\"o}ckel and Bahriye Aktas and Andreas Schneeweiss and Rachel W{\"u}rstlein",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2022",
month = feb,
doi = "10.1055/a-1724-9639",
language = "English",
volume = "82",
pages = "206--214",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "2",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2021 Part 4 - Prevention and Early Stages

AU - Thomssen, Christoph

AU - Fehm, Tanja N

AU - Stickeler, Elmar

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Kolberg-Liedtke, Cornelia

AU - Kolberg, Hans-Christian

AU - Lüftner, Diana

AU - Müller, Volkmar

AU - Schütz, Florian

AU - Belleville, Erik

AU - Bader, Simon

AU - Untch, Michael

AU - Welslau, Manfred

AU - Thill, Marc

AU - Hartkopf, Andreas D

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P

AU - Wöckel, Achim

AU - Aktas, Bahriye

AU - Schneeweiss, Andreas

AU - Würstlein, Rachel

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2022/2

Y1 - 2022/2

N2 - This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In triple-negative disease, data were presented for two treatment regimens. Patients with advanced disease (stage 2 and 3) benefit from neoadjuvant treatment with the immune checkpoint inhibitor pembrolizumab in combination with standard chemotherapy, regardless of PD-L1 expression. When neoadjuvant therapy has failed to achieve the desired remission in BRCA1 and BRCA2 mutations, the administration of the PARP inhibitor olaparib has demonstrated an impressive response. Other data address translational issues in HER2-positive breast cancer and neoadjuvant therapy approaches with the oral SERD giredestrant and the PARP inhibitor talazoparib. This review presents and analyses the findings of this year' s most important study outcomes.

AB - This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In triple-negative disease, data were presented for two treatment regimens. Patients with advanced disease (stage 2 and 3) benefit from neoadjuvant treatment with the immune checkpoint inhibitor pembrolizumab in combination with standard chemotherapy, regardless of PD-L1 expression. When neoadjuvant therapy has failed to achieve the desired remission in BRCA1 and BRCA2 mutations, the administration of the PARP inhibitor olaparib has demonstrated an impressive response. Other data address translational issues in HER2-positive breast cancer and neoadjuvant therapy approaches with the oral SERD giredestrant and the PARP inhibitor talazoparib. This review presents and analyses the findings of this year' s most important study outcomes.

U2 - 10.1055/a-1724-9639

DO - 10.1055/a-1724-9639

M3 - SCORING: Review article

C2 - 35169388

VL - 82

SP - 206

EP - 214

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 2

ER -